Eton Pharmaceuticals, Inc.
ETON
Rank in Stocks
#6209
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and... Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Share Price
$64.35
Last synced: 2026-11-09
Market Cap
$1.84B
Change (1 day)
13.97%
Change (1 year)
264.38%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Eton Pharmaceuticals, Inc. (ETON)
Category
Healthcare
Operating Margin for Eton Pharmaceuticals, Inc. (ETON)
Operating Margin as of November 2026 TTM: 15.44%
According to Eton Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 15.44%. At the end of 2025 the company had an operating margin of 0.09%.
Operating Margin history for Eton Pharmaceuticals, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 15.44% | 17,055.56% |
| 2025 | 0.09% | -101.35% |
| 2024 | -6.66% | 76.66% |
| 2023 | -3.77% | -90.30% |
| 2022 | -38.87% | 467.45% |
| 2021 | -6.85% | -99.99% |
| 2020 | -69,515.38% | 3,483.97% |
| 2019 | -1,939.62% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -98.74% |
DE
|
|
| 19.68% | -98.73% |
DE
|
|
| 13.26% | -99.14% |
JP
|
|
| 17.08% | -98.89% |
CH
|
|
| 14.92% | -99.03% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Eton Pharmaceuticals, Inc.'s operating margin
What is Eton Pharmaceuticals, Inc.'s operating margin?
Eton Pharmaceuticals, Inc.'s operating margin is 15.44%, as of Nov 2026.
What was Eton Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Eton Pharmaceuticals, Inc.'s operating margin was 0.09%, compared with -6.66% in 2024.
How has Eton Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Eton Pharmaceuticals, Inc.'s operating margin was highest in 2025 (0.09%) and lowest in 2020 (-69,515.38%).
How does Eton Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Eton Pharmaceuticals, Inc.'s operating margin (15.44%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.